FourThought Financial’s InMed Pharmaceuticals INM Stock Holding History

FourThought Financial’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	-$1K	–	1528
2021 Q3	$1K	Hold	1	–	–	﹤0.01%	1457
2021 Q2	$1K	Hold	1	–	–	﹤0.01%	1448
2021 Q1	$1K	Hold	1	–	–	﹤0.01%	1415
2020 Q4	$1K	Buy	+1	New	+$1.62K	﹤0.01%	1400

Other funds holding INM

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

AWM

AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

RFA

Reilly Financial Advisors La Mesa, California $1.35B AUM 22.65% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

FourThought Financial's INM Position: Q4 2021 in Review

FourThought Financial sold out of InMed Pharmaceuticals (INM) in Q4 2021, closing a stake of 1 share — an estimated $1K sold.

FourThought Financial first reported a position in INM in Q4 2020 and held it in 4 quarters. The position peaked at $1K in Q3 2021. 12 funds tracked by Wall St. Rank hold INM as of Q4 2021.

FourThought Financial reported no remaining InMed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
FourThought Financial sold 1 InMed Pharmaceuticals share in Q4 2021, an estimated $1K.
FourThought Financial first reported a position in InMed Pharmaceuticals in Q4 2020 and held it in 4 quarters.
FourThought Financial's InMed Pharmaceuticals position peaked at $1K in Q3 2021.
12 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q4 2021.

Based on FourThought Financial's 13F filing for Q4 2021, filed 14 Jan 2022.